NanoViricides, Inc.

Healthcare · Biotechnology · United States

Last price 1.4 USD (Oct 30, 2026, 10:20 AM EDT) · Market cap 35.74M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection...